Biofrontera and Schering work together against stroke

Drug discovery and development company Biofrontera Pharmaceuticals, of Leverkusen in Germany has entered into a long-term collaboration with Schering to discover and develop new drugs for the treatment of stroke, following validation of Biofrontera's integrated technologies by Schering.

The deal is said to be worth several million Euro in milestone payments as well as royalty payments on drug sales.

Biofrontera will analyse the cascade of molecular events following an artificially induced stroke in animals. To discover and validate targets for new drugs, Biofrontera's gene expression profiling technology, DEPD, and sophisticated bioinformatics will be applied to an in-depth analysis of the initial, intermediate, and late pathological changes relevant to the disease. Following the identification of interesting targets, Schering and Biofrontera will continue to co-operate in the discovery and development of lead structures interacting with these targets.